Serious as Cancer
The New York Times's May 3 front-page story on a potentially imminent cure for cancer has given the paper its worst publicity blitz since 1991, when the Times printed the name of the woman who accused William Kennedy Smith of rape.
Gina Kolata's article on the research of Dr. Judah Folkman raised eyebrows--and then, almost immediately, serious questions about Kolata's reporting and motives. Here is a summary of seven stormy days in May:
The morning after the story's publication, Kolata's literary agent had a book proposal on editors' desks at major publishing houses, which incorporated the "news" that had just been published. The following day, after questions surfaced concerning the article and Kolata discussed the potential book project with her Times editors, the proposal was withdrawn.
Nobel laureate Dr. James D. Watson wrote a letter to the Times, declaring that he had been substantially misquoted over something said casually at a dinner party six weeks before. Watson's office told the Voice that he was never informed he was speaking for publication, and that no one from the Times called him prior to the article's publication to verify any aspect of what he'd said.
Kolata and the Times insist that the quote is "accurate." Thus, the Times is contradicting the public account that one of the world's most respected scientists has given of his own words, even while admitting that Kolata did not takes notes while Watson was speaking and never checked the quote's veracity with him. Kolata's Times story even got Watson's title wrong, as a Friday correction noted.
Richard Klausner, head of the National Cancer Institute, also had his words botched in the Times, prompting a correction about "an imprecise paraphrase."
On Friday, following two days of critical coverage in the Los Angeles Times and Newsday, the Times was forced to publish an exceptionally rare article about the conflict-of-interest accusations being leveled at its own reporter. On the same day, the Boston Globe published a front-page article saying the Timesstory's unbridled optimism on the sober topic of cancer "suggests the need for media moderation on the medical front." This marks the first time since the Times bought the Globe in 1993 that a page-one Globe story has directly tweaked the judgment of its corporate parent.
As this week began, a Newsweek cover article declared that the "Times story, whose front-page placement belied the fact that it contained little that had not been reported already, itself became the story." TheNew Yorker's May 18 Comment column noted that the fundamental facts of Kolata's story had already been reported in the Times last November on page A28. TheNew Yorker headline summed it up: "Forget cancer. Is there a cure for hype?"
Of all the charges leveled at the Times and Kolata, the notion that she hyped the cancer-cure story for a book advance is probably the most serious. In the middle of the week, Random House promised $1 million to Newsday reporter Robert Cooke for a book on the same topic, and Kolata's agent reportedly said he could get her $2 million for a two-page e-mail proposal, so the stakes are extremely high.
If Kolata's account is true, her agent acted largely on his own after the story was published. Since she and her editors concluded that a new book project--she is already under a separate contract--would interfere with her ability to report this story, it doesn't seem that Kolata bent any ethics rules for her own book purposes.
It's harder, though, to acquit Kolata on the charge that she misquoted Dr. Watson, one of the scientists credited with discovering the structure of DNA. In his letter to the Times, Watson said that "at a dinner party six weeks ago" he said to Kolata that the two drugs would be in clinical trials in a year, and that after another year, the scientific community would know whether or not they were effective. That's a far cry from saying "Judah is going to cure cancer in two years," which is how Kolata rendered his remark.
The Times is obviously concerned about implying--if not out-and-out saying--that this Nobel laureate is fibbing. "We don't wish to be in a position of quarrelling with him," Times publicist Nancy Nielsen said.But there's no middle ground--either Watson or Kolata is wrong.
Some at the Times and elsewhere have argued that Watson has his own interest in backpedaling, since a provocative comment might well earn him scorn from colleagues. As a general policy, the Times, like many other papers,says it's concerned that "when sources are confronted with their words, they often try to backtrack."
And Watson has in the past distanced himself from remarks in the papers. As the Long Island Voice noted last year, Watson wrote a similar letter disputing a British Daily Telegraph report attributing to him the view that women should be allowed to abort fetuses determined to be homosexual (assuming such screening was possible).
But even if Watson's letter to the Times was backpedaling--and it's very much in dispute--Kolata's reporting was astonishingly lax. Watson's office told the Voice that he was not informed at the dinner party he would be quoted in the Times, and there was no attempt to follow up the conversation.
Few newspapers have fact-checkers, and clearly daily reporters rarely have the luxury of double-checking their notes or memories with the sources they're quoting. But as a Sunday page-one feature, Kolata's story took days--if not weeks--to prepare. Under those circumstances, Times reporters often call back sources to make sure they've got it right, though the paper says such calls are "a matter of each reporter's discretion, case by case."
A Voice call to Kolata seeking comment was returned by Times publicist Nielsen. "We're confident in the accuracy of the story," she said, including the "accuracy of [Watson's] quote." What about Watson's assertion that he did not know he was speaking for attribution? "He knew who he was talking to," Nielsen said.
What's distressing is that this is not the first time Kolata's been accused of misquotation. Jonathan Kwitny's 1992 book Acceptable Risks--which recounts the controversial efforts of two activists to administer unapproved drug treatments to people with AIDS--cites several people who said Kolata misquoted them in Times coverage of the same topic.
Kwitny, a former Wall Street Journal reporter, found Kolata's stories "certainly not typical of The New York Times's methods," and wrote: "It is a painful portrait of my profession, journalism, and should be seen by the reader not as what the profession usually does, but as what it is sometimes capable of and must guard against."
Those words sound uncomfortably similar to the assessment made last week of Kolata's current work.
60 Minutes got a little mud on its stopwatch face last week, when the British daily Guardian published an enormous exposé about a documentary called The Connection. The Connection was shown on Cinemax last June (here renamed The Drug Run), and previewed exclusively on 60 Minutes in a segment called "The Mule," which was approved by the show's executive producer Don Hewitt.
The Guardian story claims that nearly every aspect of the film--which purported to show associates of the Cali cartel using a new heroin smuggling route from Colombia to Britain--was faked. The bags of "heroin" the drug "mule" swallowed for the camera were, according to a Guardian interview with the mule himself, filled with Certs candies (Marc De Beaufort, the producer, has acknowledged that he didn't verify that the powder was actually heroin). The men captured on film did not fly, as the film claimed, from Colombia to London in a single trip; in fact, they didn't go to London until six months after the initial scenes were shot.
How did 60 Minutes deal with the suggestion it was duped? The show ran this tiny "update" on Sunday: "This week the British newspaper The Guardian charged that the highly acclaimed documentary was a fraud. The program's producer denies the allegation, and Carlton TV, which distributed the film worldwide, says it is investigating. We'll keep you posted."
Granted, if 60 Minutes was hoodwinked, it was not alone, and its on-air snippet is more than HBO-Cinemax has done to date. But viewers were given absolutely no sense of the details of the Guardian series. Nor were they told that producer De Beaufort, while defending himself, admits the segments of the film 60 Minutes used were not what they claimed to be.
60 Minutes spokesperson Kevin Tedesco described the situation as a "he said, she said" dilemma that can be resolved only when "senior producers" from 60 Minutes conduct their own investigation. He said that neither correspondent Steve Kroft nor producer John Hamlin--who cut the Cinemax film into the 60 Minutes segment--would be available to discuss how this alleged charade got on the air. That, alas, is exactly the kind of stonewalling one expects 60 Minutes to knock down. Make up your own mind: read the entire Guardian series at www.guardian.co.uk.
Why should anyone believe what they read in The New Republic? Monday's Washington Post carried an extremely embarrassing story noting that TNR editor Charles Lane had to fire 25-year-old associate editor Stephen Glass "for fabricating characters and situations'' in at least five TNR stories. The mag claims to have fact-checkers, but Glass evidently fooled them. A Forbes Web sitestory said that Glass and his brother "concocted a fake corporate site . . . on America Online, in addition to phony voice and E-mail accounts for all his sources." This, of course, comes on top of the many instances of plagiarism charged to TNR associate editor Ruth Shalit. Why not just change the "associate editor" title to "associate liar"?
Research: Kaelen Wilson-Goldie
Get the This Week's Top Stories Newsletter
Every week we collect the latest news, music and arts stories — along with film and food reviews and the best things to do this week — so that you’ll never miss Village Voice's biggest stories.
- NYU Student Employees Say the University Hasn't Paid Them in Months
- Here Are the Early Frontrunners for Worst Halloween Costumes for Sale in New York
- How Does the DEA Determine the Value of Confiscated Marijuana?